

FIG. 1A




FIG. 1B




FIG. 2




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 4




FIG. 5




FIG. 6




FIG. 7A




FIG. 7B




FIG. 7C




FIG. 7D

- Group 1: Vehicle Control
- ▨ Group 2: Ab7 (25mg/kg)
- ▩ Group 3: Ab1 (25mg/kg)
- ▧ Group 4: Ab8 (25mg/kg)
- ▦ Group 5: Ab9 (25mg/kg)




FIG. 8A




FIG. 8B




FIG. 8C

- Group 1: Vehicle Control
- ▨ Group 2: Ab7 (25mg/kg)
- ▩ Group 3: Ab1 (25mg/kg)
- ▧ Group 4: Ab8 (25mg/kg)
- ▦ Group 5: Ab9 (25mg/kg)




FIG. 9A

- ◆ PBS
- IgG ctl (60 mg/kg/wk)
- ▲ Ab1 (60 mg/kg/wk)
- ▼ Ab1 (20 mg/kg/wk)
- ◇ Ab1 (6 mg/kg/wk)
- Ab1 (2 mg/kg/wk)




FIG. 9B




FIG. 10A

FIG. 10B




FIG. 10D

FIG. 10C




FIG. 11A

FIG. 11B




FIG. 12A

FIG. 12B




FIG. 12D

FIG. 12C




FIG. 13B




FIG. 13A




FIG. 14A

FIG. 14B





FIG. 14C

FIG. 14D



Error bars represent Standard Error of the Mean (SEM)
Statistical analysis: One way ANOVA (Dunnnett's multiple comparisons test)

FIG. 15




FIG. 16B




FIG. 16A




FIG. 17B




FIG. 17A




FIG. 18A





FIG. 18B

Muscle	Ab	PBS Ctl	20 mg/kg/wk	2 mg/kg/wk	0.5 mg/kg/wk
Gastrocnemius	Ab1	0	25.1	13.0	14.9
Gastrocnemius	Ab2	0	25.6	24.0	9.8
Gastrocnemius	Ab4	0	25.0	15.0	3.1
Gastrocnemius	Ab6	0	24.8	9.3	7.4
Quadriceps	Ab1	0	23.9	13.9	10.8
Quadriceps	Ab2	0	23.9	26.1	7.6
Quadriceps	Ab4	0	37.8	6.4	0.2
Quadriceps	Ab6	0	32.0	0.4	0.2

FIG. 18C



901




FIG. 20

1 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYY 60
 61 ADSVKGRFTISRDNSKNTFLYLQMNSLRAEDTAVYYCARDLLVRFLEWSHYYGMDVWGQGT 120
 121 TVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFP 180
 181 AVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEF 240
 241 LGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSEQEDFEVQFNWYVDGVEVHNAKTKPREE 300
 301 QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPS 360
 361 QEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLSDGSFFLYSRLTVDK 420
 421 SRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG 452

FIG. 21A

1 QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVHWYQQLPGTAPKLLIYSDNQRPSGVP 60
 61 DRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGVFGGTKLTVLGQPKAAPSVTL 120
 121 FPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTTPSKQSNNKYAASSY 180
 181 LSLTPEQWKSHRSYSQCQVTHEGSTVEKTVAPTECS 215

FIG. 21B




FIG. 22




FIG. 23A





FIG. 23B



Top 12 clones selected for further characterization

Ab1:	4.8 nM	
Ab4:	0.47 nM	10-fold improved
Ab6:	0.48 nM	10-fold improved
Best affy matured mAb:	<10 pM	>480-fold improvement

FIG. 23C

	FRAMEWORK 1	CDR1	FRAMEWORK 2
Ab1	QIQLVQSGGGVVQPGRSLRLSCAAS	<u>SGTTFSSYGMHWVRQAPGKGLEWVA</u>	
Ab3	QIQLVQSGGGVVQPGRSLRLSCAAS	<u>SGTAFSSYGMHWVRQAPGKGLEWVA</u>	
Ab5	QIQLVQSGGGVVQPGRSLRLSCAAS	<u>SGTAFSSYGMHWVRQAPGKGLEWVA</u>	
	CDR2	FRAMEWORK 3	
Ab1	<u>VISYDGSNKYYADSVKG</u>	RFTISRDN SKNTLYLQMNSLRAEDTAVYYCAR	
Ab3	<u>VISYDGSNKYYADSVKG</u>	RFTISRDN SKNTLYLQMNSLRAEDTAVYYCAR	
Ab5	<u>VISYDGSNKYYADSVKG</u>	RFTISRDN SKNTLYLQMNSLRAEDTAVYYCAR	
	CDR3	FRAMEWORK 4	
Ab1	<u>DLLVRFLWSHYYGMDV</u>	WGQGT TVTVSS	
Ab3	<u>DLLVRFLWSHYYGMDV</u>	WGQGT TVTVSS	
Ab5	<u>DLLVRFLWSHYYGMDV</u>	WGQGT TVTVSS	

FIG. 24A

	FRAMEWORK 1	CDR1	FRW2
Ab1	QPVLTPPPSASGTPGQRTISCSGSS	<u>SNIGSNTVHWYQQLPGTAPKLLIY</u>	
Ab3	QPVLTPPPSASGTPGQRTISCSGST	<u>SNIGSNTVHWYQQLPGTAPKLLIY</u>	
Ab5	QPVLTPPPSASGTPGQRTISCSGSS	<u>SNIGSNTVHWYQQLPGTAPKLLIY</u>	
	CDR2	FRAMEWORK 3	
Ab1	<u>SDNQRP</u>	SGVPDRFSGSKSGTSASLVISGLQSDDEADYYC	
Ab3	<u>SDDQRP</u>	SGVPDRFSGSKSGTSASLVISGLQSDDEADYYC	
Ab5	<u>SDDQRP</u>	SGVPDRFSGSKSGTSASLVISGLQSDDEADYYC	
	CDR3	FRAMEWORK 4	
Ab1	<u>AAWDDSLNGV</u>	FGGGTKLTVL	
Ab3	<u>AAWDESLNGV</u>	FGGGTKLTVL	
Ab5	<u>AAWDESLNGV</u>	FGGGTKLTVL	

FIG. 24B




FIG. 25




FIG. 26




FIG. 27




FIG. 28A




FIG. 28B




FIG. 29




FIG. 30A




FIG. 30B




FIG. 31A




FIG. 31B





FIG. 32



	$t_{1/2}$ (day)	AUC_{INF} (day*ug/mL)
AbMyo	8.2	773
Ab2	20.3	2072

FIG. 33




FIG. 34




FIG. 35A




FIG. 35B




FIG. 36A




FIG. 36B